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Abstract 
Despite major improvements in pharmacological and device treatments, heart failure remains a 
syndrome with a high morbidity and mortality, a poor quality of life, and high health care costs. Given  
extensive heterogeneity among patients with heart failure, substantial differences in the response to 
therapy can be expected. We hypothesize that individualized therapy is an essential next step to 
improve outcomes in patients with heart failure. BIOSTAT-CHF uses a novel systems biology approach to 
develop a model that predicts response to therapy, incorporating demographics, biomarkers, genome-
wide analysis, and proteomics. For this purpose, we included 2516 patients with worsening signs and/or 
symptoms of heart failure from 11 European countries, who were considered to be on suboptimal 
medical treatment. Another 1738 patients from Scotland were included in a validation cohort. Overall, 
both patient cohorts were well matched. The majority of patients were hospitalised for acute heart 
failure, and the remainder presented with worsening signs and/or symptoms of heart failure at the 
outpatient clinic. Approximately half of the patients in NYHA class III and 10-15% of patients had HFpEF. 
According to study design, all patients used diuretics, but due to the inclusion criteria of both cohorts, 
patients were not on optimal, evidence-based medical therapy: 70/72% used an ACE-
inhibitor/Angiotensin Receptor Blocker, and < 50% used the optimal dose. Beta-blockers were used in 
73/83% of patients and only 32/46% used the optimal dose. The predictive models for response to 
therapy are required to evaluate and test alternative therapies for patients with a suboptimal response 
and thus improve care for patients with heart failure. BIOSTAT-CHF was funded by a grant from the 
European Commission (FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29)  
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Introduction 
Despite advances in the treatment of patients with heart failure, the prognosis of patients with 
worsening symptoms of heart failure remains poor with up to 40% being dead or readmitted to hospital 
within 1 year. (1-4) In a recent European Survey in patients with chronic stable heart failure, more than 
17% of patients died or were hospitalized for heart failure within a year.(5) Prognosis is even worse in 
patients admitted for acute heart failure. In the same registry, one year mortality or heart failure 
hospitalization in patients admitted for acute heart failure was more than 35%. (5) Similar mortality 
rates have been shown in other registries, which also showed that 30-40% of patients were re-
hospitalized within 1 year after hospital admission.(2) Thus, although the prognosis of heart failure 
patients has improved, mortality and rehospitalisation remain high, especially in patients with 
worsening signs and/or symptoms of heart failure. 
There are several explanations for the persistent high mortality and morbidity in patients with 
worsening signs and symptoms of heart failure. First, patients are often not optimally treated due to 
compliance of patients and health care providers. Second, better treatments might be needed to further 
improve clinical outcome.  However, it is generally observed that the absolute effect of new 
pharmacological agents has declined over the last 2 decades.(6) In addition, from 2004- 2010, several 
large drug trials in patients with heart failure failed to show any benefit.(7-9) This may reflect the 
increased difficulty to further reduce mortality and morbidity, on top off effective drugs, the so-called a 
law of diminishing returns.  
We propose that future significant improvements can  be achieved when therapy is individualized and 
tailored to the patient’s profile. Given the large heterogeneity of patients with heart failure with 
multiple aetiologies, cardiac phenotypes and co-morbidities, a currently advocated one-size-fits-all 
approach is not appropriate in every patient. Large randomized clinical trials might show an overall 
beneficial effect, but treatment may not necessarily be beneficial in every patient subgroup. A successful 
trial just means that significantly more people benefitted. Many patients will never experience the 
endpoints captured and treatment may have made no difference to their outcome. The residual high 
mortality and morbidity reflect groups of patients who do not benefit from existing therapies.  
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Main objectives of BIOSTAT-CHF 
The main aim of BIOSTAT-CHF is to characterize biological pathways related to response/no-response to 
guideline-recommended pharmacological therapy for heart failure. Patients will be profiled at several 
levels, including clinical characteristics, genetic background, and protein expression. Using a systems 
biology approach, these levels will be integrated to search for pathways which may explain the 
individual patient response to therapy.  
 
Design of BIOSTAT-CHF 
The design of the BIOSTAT-CHF project is presented in figure 1. In brief, from an index cohort of 2516 
patients (Work Package 2 and 6), information was collected to create a risk score for non-response to 
therapy defined as death or heart failure hospitalization. This information includes blood and urinary 
biomarkers (Work Package 3), proteomics (Work Package 4) and genomics (Work Package 5). The score 
will be made using a systems biology approach (Work Package 7). The score will then be validated in a 
second cohort of 1738 patients (Work Package 8).   
 
Index cohort 
Study design 
This was a multicenter, multinational, prospective, observational study. The study population consisted 
of 2516 patients from 69 centres in 11 European countries. For the list of centres and the investigators, 
see appendix 1. The recruitment period was 24 months, starting from December 2010. The last patient 
was included on December 15, 2012. Median follow-up was 21 months [interquartile range 15-27 
months] .  
 
Study population 
- Patients were aged ≥18 years with symptoms of new-onset or worsening heart failure 
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- They had objective evidence of cardiac dysfunction documented either by 
o left ventricular ejection fraction of ≤40%  OR 
o plasma concentrations of BNP and/or NT-proBNP  >400 pg/ml or >2,000pg/ml, 
respectively 
- They were treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the 
time of inclusion 
- Not previously treated with evidence based therapies (ACEi/ARBs and beta-blockers) or  
receiving ≤50% of the target doses of these drugs at the time of inclusion 
- Were anticipated to be  initiated or up-titrated with ACEi/ARBs and/or beta-blocker therapy by 
the treating physician 
Patients could be enrolled as in-patients or from out-patient clinics.  
- Exclusion criteria were the following: known diagnosis of septicaemia, known diagnosis of acute 
myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy, heart 
transplant recipient or admitted for cardiac transplantation or LVAD surgery, anticipated need of 
surgery or any cardiovascular intervention, except implantable cardioverter defibrillator and/or 
cardiac resynchronization therapy, within 4 weeks, current known inability to follow instructions 
or comply with follow-up procedures, treatment with medications or devices not approved in 
Europe. Patients with concomitant pulmonary disease, even if severe, valvular disease, acute 
coronary syndrome or stroke, could be included when the primary diagnosis for admission to 
hospital or outpatient clinic visit was heart failure, rather than the concomitant condition. 
 
Main study endpoints 
All deaths and hospitalizations were recorded. The primary outcome of interest was time to a composite 
of death or unscheduled hospitalizations for heart failure. The heart failure hospitalizations were 
determined by the investigator, and were not adjudicated by a central adjudication committee.  
 
Study Plan 
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Eligible patients signed informed consent and were included in the study. Medical history, current use of 
medication, and a physical examination were recorded at baseline. All patients underwent a 6-minute 
walk test and completed EQ5D and KCCQ questionnaires. Plasma and serum (total of 80cc) and urine 
were sampled for analysis. Performance of standard echocardiography was strongly recommended but 
not mandatory for inclusion into the study. The study recorded changes in the use of medication. During 
the first three months the investigators were required to optimize treatment of heart failure, including 
the initiation of evidence based therapies and the up titration of current therapies to the doses 
indicated in the European Society of Cardiology 2008 guidelines.(10) The subsequent 6 months were 
considered as the maintenance phase and no further treatment optimization was predicted, except in 
case of changes in the clinical status. At 9 months, a second study-mandated visit was performed. 
Current symptoms and medication were recorded, a physical examination, 6-minute walk test, and 
EQ5D and KCCQ questionnaires were completed and more blood was collected.  Patients were 
subsequently followed, by standard clinic follow-up or telephone contact after intervals of 6 months, 
until the end of follow-up on April 1, 2015.   
 
Validation cohort 
Study design 
The BIOSTAT-CHF validation cohort was designed as a multicenter, prospective, observational study. The 
study population consisted of 1738 patients from 6 centres in Scotland, UK. For the list of centers and 
the investigators, see appendix 2. The recruitment period started in October 2010 and was completed in 
April 2014. Median follow-up was 21 months [interquartile range 11-32 months].  
 
Study population 
- Patients were aged ≥18 years with a diagnosis of heart failure based on  
o Echocardiographic evidence of left ventricular systolic dysfunction 
o A previous documented admission with heart failure requiring diuretics 
- Were on treatment with furosemide ≥20 mg/day or equivalent 
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- Were not previously treated or receiving ≤50% of target doses of ACE inhibitors/ARBs and/or 
beta-blockers according to the European Society of Cardiology 2008 guidelines. 
- There was an anticipated initiation or up-titration of an ACEi/ARB and/or a beta blocker 
- Patients could be enrolled as in-patients or from out-patient clinics.  
 
Main study endpoints 
All deaths and hospitalizations were recorded. The primary outcome of interest was time to a composite 
of all-cause death or unscheduled hospitalizations for heart failure during follow-up. The heart failure 
hospitalizations were determined by the investigator, and were not adjudicated by a central 
adjudication committee. 
 
Study Plan 
Following written Informed Consent the following assessments were performed: demographics 
(including medication), EQ5D and KCCQ Quality of Life Questionnaires were issued for completion by the 
patient, a medical history and physical examination, and blood draw of approximately 80 cc of plasma 
and serum, a urine specimen and a 12-lead resting ECG. If not already performed, an echocardiogram 
was performed by the clinical research fellow.  
 
Biomarkers 
Biomarkers from several pathophysiological domains were measured, including markers of 
inflammation, apoptosis, remodelling, myocyte stress/injury, angiogenesis, endothelial function, and 
several markers of renal function. For an overview of all novel and traditional biomarkers available in 
BIOSTAT-CHF, please see table 2.  
 
Proteomics 
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Proteomics and peptidomics were performed using high resolution mass spectrometry (MS) to enable 
highly accurate mass determination of ions to study the proteome of plasma, using two soft ionisation 
techniques, MALDI (matrix assisted laser desorption and ionisation MS) for peptidomics and ESI 
(electrospray ionisation) for bottom-up proteomics using two-dimensional liquid chromatography high-
definition MS (2D LC HDMS, with ion mobility spectroscopy). A series of informatics software packages 
were used to identify and quantify proteins from the highly complex data generated from the 2D LC 
HDMS. Machine learning algorithms employing support vector machines, neural networks or decision 
forests as the core classifier were employed on the high-dimensional peptidomic data, to seek predictive 
models for responder status. In addition, evolutionary search methods (genetic algorithms) were utilised 
to reduce the peptidomic feature set to those that are most effective at classification. Detailed 
bioinformatic analyses of the 2D LC HDMS data were performed on a subset of the patient cases 
showing good or poor outcomes, in order to formulate the optimal set of predictive protein features.  
These candidate proteins were verified using immunoassay or selected reaction monitoring. From this, a 
set of immunoassays was devised for the best 10 candidate proteomic biomarkers to be tested on the 
index and validation cohort. 
 
Genomics 
A Genome Wide Association Study (GWAS) was performed in the discovery cohort and follow-on studies 
in the replication cohort to identify genetic variants that contribute to the clinical response and outcome 
of patients included in BIOSTAT-CHF. The GWAS platform was chosen to provide coverage of both 
common and lower frequency exomic variants. . In addition to identifying independent genetic loci that 
influence outcome, the findings from the GWAS will be integrated into the development of the general 
score, the principal aim of BIOSTAT-CHF. 
 
Sample size justification 
The cardiac event rate was expected to be 35% during the median follow-up of 18 months.(2-5) In 
addition, dichotomizing the therapy-response variables at six months, we estimated that about 50% of 
the patients will respond to their treatment (i.e. patients will not die or have to be hospitalized for 
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worsening heart failure). The predictive models were based on between 875-1250 primary events. For 
the univariable analyses of the associations between SNPs, proteins and biomarkers versus cardiac 
events the index sample size provides >80% power if the odds ratio between a SNP and response/event 
is 1.4 or if the effect size of a protein/biomarker is 0.12 when using a significance level of 0.05. But when 
corrected for the multiple testing on about 500,000 variables the odds ratio and effect size need to be 
>2.1 and 0.26, respectively, to provide at least 80% power. It is likely therefore that the index cohort will 
not identify any definitive hits but will identify a large number of risk markers with suggestive 
associations with outcomes. These will be taken forward to replication and only those markers showing 
a combined (discovery + replication) P value will be considered confirmed.  
 
Statistics and Systems biology risk model 
Predictive models for the treatment outcomes will be developed in two ways, using classical statistical 
methods and by using system biological or computational models based on available knowledge of 
myocardial adaptation and medication metabolism. The primary outcomes of treatment are all-cause 
mortality and unplanned hospitalization for heart failure, but we also will consider clinical and functional 
outcomes on metrics such as NYHA class, left ventricular ejection fraction, blood pressure, quality of life 
and the six-minute walk test. Development of the predictive models will start with evaluation of 
univariable associations between the treatment outcome and clinical variables, genetic and 
biomolecular markers and the protein expressions as assessed at the baseline visit. To limit the family-
wise error rate due to multiple testing we will lower the overall significance level such that the false 
discovery rate is between 5% and 10%. We will use permutations to estimate the false discovery rate 
(FDR) and the p-values. Multiple regression analyses will next be used to select the independent 
predictors of treatment outcome. We will develop ensembles of different statistical and machine-
learning tools such as linear and logistic regression, neural networks, regression trees, random forests 
and support vector machines. Variable selection will be done with lasso regularization and the optimal 
lasso-penalties will be determined with cross-validation. Weights for the different regression tools in the 
ensembles will also be determined with cross-validation. Since the different treatment outcome 
parameters will be correlated we will also use multivariate regression techniques to develop predictive 
models: we will in particular use penalized canonical correlation analysis and partial least squares. 
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Our second approach to develop predictive models for treatment outcomes will be based on the 
available measurements of clinical, biomolecular and genetic markers and current knowledge of the 
pathways involved in myocardial adaptation and the effect of medication/treatment on these pathways. 
We will use simple causal statistical models for the treatment outcomes by explaining how pathogenic 
pathways involved in heart failure are modulated by heart failure medication.(Figure 3) 
Pathogenetic pathways on development and progression of heart failure will be mined from available 
knowledge-bases such as NCBI, KEGG, Gene Ontology, and SwissProt. The KEGG database, for example, 
currently lists several pathways leading to heart failure among which are the pathways for dilated 
cardiomyopathy (map05414) and hypertrophic cardiomyopathy (map05410). Available genetic and 
biomolecular markers and proteins that are part of the selected pathways will be modelled using 
Bayesian network analyses and associated as a whole with the treatment outcomes. In addition, we will 
use global testing and gene-enrichment approaches to test the involvement of associated pathways 
such as the renin-angiotensin system, the TGFB-signalling pathway and inflammatory pathways. To 
predict how the different heart failure medications influence these pathogenetic pathways of heart 
failure, we will associate these pathways with known metabolic pathways of medications. The metabolic 
pathways will be mined from NCBI, KEGG, Gene Ontology, PharmGkb and several interaction databases 
such as Swissprot, Reactomes, Interactome, and BioGrid. Pharmacodynamics and bioavailability of the 
heart failure medications and their associations with genetic markers will be mined from PharmGkb. 
Baseline characteristics of the index and validation cohort 
Baseline characteristics of the patients in the index (n=2516) and validation cohort (n=1738) are 
presented table 1. Patients in the index cohort were younger and more often male, but overall both 
cohorts were well matched. The majority of patients were hospitalised for acute heart failure, and the 
remainder (index cohort: 32.6%; validation cohort: 46.3%) presented with worsening signs and/or 
symptoms of heart failure at the outpatient clinic. At inclusion, 44/48% of patients were in NYHA class III 
and 10-15% of patients had HFpEF. According to study design, all patients used diuretics, but due to the 
inclusion criteria of both cohorts, patients were not on optimal, evidence-based medical therapy: 
70/72% used an ACE-inhibitor/Angiotensin Receptor Blocker, and < 50% used the optimal dose. Beta-
blockers were used in 73/83% of patients and only 32/46% used the optimal dose.  
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Discussion 
From the 1980s to now, the outcome of heart failure patients has tremendously improved. The 
introduction of ACE-inhibitors, beta-blockers, angiotensin receptor blockers and mineralocorticoid 
receptor antagonists have resulted in symptom improvement and a lower risk for mortality and hospital 
admission for worsening heart failure. Medical devices, such as ICDs and cardiac resynchronization 
therapy further improved outcomes. Therefore, it will be more difficult to make further progression in 
the treatment of patients with heart failure. Given the large heterogeneity of patients with heart failure, 
a one-size-fits-all approach is likely not lead to major further improvements. We suggest that future 
significant improvements can only be achieved when therapy is individualized and tailored to the 
patient’s profile.  
At present, individualized medicine is already carefully applied in patients with heart failure. Cardiac 
resynchronization therapy is only recommended in patients with a QRS width>130 ms and patients with 
a left bundle branch block seem to respond better.(3) Ivabradine is only recommended in patients with 
a higher heart rate and are in sinus rhythm.(3) Recent and ongoing trials in acute heart failure are aimed 
at patients with a systolic blood pressure >125 mmHg. (11,12)  However, these examples are based on 
the mode of action of the drug, and is only aimed at major and expected response profiles.  
To detect unexpected response profiles, unbiased approached are needed. Multiple large phase III 
randomized clinical trials provide pre-defined subgroup analyses, which are usually presented by Forest 
plots. However, these conventional subgroup analyses based on clinical characteristics often failed to 
demonstrate any interaction effects with treatment. One exception is that African-American heart 
failure patients seem to respond less well to ACE-inhibitors. (13) Similar findings were observed on the 
response of African American patients to angiotensin receptor blockers. A few other examples of patient 
characteristics that influence the response to therapy have been described in a recent review.(14) 
Biomarkers have become increasingly important in evaluating the diagnosis, prognosis and phenotype of 
patients with heart failure(15-18), but they might also predict the response to therapy. For example, in 
patients with chronic heart failure and elevated renin levels, ACE-inhibitors cause a marked diuresis, 
which is not observed in patients with low renin levels.(19) Similarly, the blood pressure lowering effects 
of several groups of anti-hypertensive drugs is highly associated with plasma renin activity.(20)  
Interestingly, the less pronounced response of African American patients to ACE inhibition might be due 
to their lower renin activity.(21) Several genetic variations have also been related to the response to 
heart failure therapy. For example, patients with the Arg389Arg genotype showed a marked 
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improvement in survival and reduction in hospitalization on the beta-blocker bucindolol, while only a 
minimal impact was evident in patients either homozygous or heterozygous for the Gly389 allele.(22) 
Other examples of genes influencing the response to therapy are depicted in figure 2 and reviewed 
elsewhere.(14) 
In summary, the individualized response to a drug can be studied on different levels, such as on a 
genetic, proteomic, and phenotypic level. However, as depicted in figure 1, these levels are internally 
related to each other. For example, there are several genetic variations that are related to the activity of 
the renin-angiotensin system, which define several phenotypes of patients with a better or worse 
response to inhibitors of the renin-angiotensin system.(Figure 2) 
 
BIOSTAT-CHF aims to integrate demographics, established biomarkers, proteomic, and genetic 
information to achieve a better assessment of the individual patient’s characteristics, response to 
therapy and prognosis. This necessitates either the discovery of new markers and/or their integration 
with known variables into a systems biology approach, which may identify groups of patients that have a 
poor response to the current recommended therapy for heart failure.   
Systems biology focuses on the complex interactions in biological systems from a new perspective; 
integration instead of reduction.(23) This approach requires the integration of experimental and 
computational research to help understand a system’s structure and dynamics. Multilevel data from 
BIOSTAT-CHF will be analyzed using logistic regression models, but also using alternatives, such as logic 
regression, neural networks, regression trees, random forests and support vector machines, to 
determine characteristics of patients that are associated with the response to current heart failure 
treatment. Taken together, using a systems biology approach, BIOSTAT-CHF aims to detect pathways 
which may explain the individual patient response to therapy.  
BIOSTAT-CHF successfully recruited an index cohort (n=2516) and a validation cohort (n-1738) of 
patients with worsening signs and/or symptoms of heart failure who were not yet optimally treated. 
These populations are at high risk for subsequent events, such as mortality and/or heart failure 
(re)hospitalization. Due to the stricter (NT-pro)BNP criteria for patients with a LVEF>40$, only 10-15% of 
the patients has HFpEF. Both cohorts were well comparable in terms of their characteristics and both 
had a median follow-up of 21 months.  
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Summary 
Although major improvements have been achieved in the treatment of patients with heart failure, 
mortality and morbidity remain high. The large variation in patient profiles, aetiology, cardiac 
phenotypes, co-morbidities and clinical presentation led to the hypothesis that not all patients will 
benefit from the same treatment. Therefore, we believe that the next step forward has to come from an 
individualized treatment approach. In BIOSTAT-CHF, two independent cohorts (n=2516 and n=1738) of 
worsening heart failure patients were recruited, their medication was optimized, and patients were 
followed for a median of 21 months. By using a novel systems biology approach we will provide a model 
that predicts response to therapy, incorporating demographics, biomarkers, genome-wide analysis, and 
proteomics. Such a predictive model should be instrumental in developing alternative therapies for 
patients with a sub-optimal response and thus improve care for patients with heart failure.  
 
Funding: This project was funded by a grant from the European Commission: FP7-242209-BIOSTAT-CHF 
 
Conflicts of Interest:  
Voors reports consultancy fees and/or research grants from: Alere, Amgen, Bayer, Boehringer 
Ingelheim, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, Servier, Stealth Peptides, Singulex, 
Sphingotec, Trevena, Vifor, ZS Pharma  
Anker reports grants from Vifor and Abbott Vascular, and fees for consultancy from Vifor, Bayer, 
Boehringer Ingelheim, Brahms, Cardiorentis, Janssen, Novartis, Relypsa, Servier, Stealth Peptides and ZS 
Pharma. 
Cleland: 
Dickstein: 
Filippatos: received fees and/ or research grants from Novartis, Bayer, Cardiorentis, Vifor, Servier, Alere, 
Abbott 
Van der Harst: research grant from Abbott. 
15 
 
Hillege: 
Lang: received consultancy fees and/or research grants from: Amgen, Astra Zeneca, MSD, Novartis, 
Servier 
Ng: none 
Ponikowski: 
Samani: None 
 Van Veldhuisen reports Board Membership fees/Travel Expenses from BioControl, Cardiorentis, 
Johnson & Johnson, Novartis, Vifor and Zoll Medical. 
Zannad: 
Zwinderman: 
Metra: Consulting honoraria from Bayer, Novartis, Servier, speaker’s fees from Abbott vascular, Bayer 
and ResMed. 
 
 
 
List of collaborators: 
WP1: Project Management team: A.A. Voors (WP-leader), S.D. Anker, J.G. Cleland, K. Dickstein, G. 
Filippatos, H.L. Hillege, C.C. Lang, MD, M. Metra, L. Ng, P. Ponikowski, N. Samani, D.J. van Veldhuisen, F. 
Zannad, A.H. Zwinderman. 
WP2: Protocols: M. Metra (WP-leader) 
WP3: Biomarkers: S. D. Anker (WP-leader) 
WP4: Genomics: N. J. Samani (WP-leader), Andrea Koekemoer (Leicester), Manolo Papakonstantinou 
(Leicester), Leanne M Hall (Leicester), Simon R Romaine (Leicester), Christopher P Romaine (Leicester), 
16 
 
John R Thompson (Leicester), Pim van der Harst (Groningen)WP5: Proteomics: L. Ng (WP-leader): D.J.L. 
Jones, R. Willingale, H.T. Cao, J.K. Sandhu, P.A. Quinn, H. Patel, J. Auluck, A. Hakimi 
WP6: Clinical Study: H.L. Hillege (WP-leader) 
WP7: Systems Biology: A.H. Zwinderman (WP-leader) 
WP8:  Validation Study: C.C. Lang (WP-leader) TAYSIDE: Prof C C Lang, Prof A D Srtuthers, Dr A M Choy, 
Dr A Doney, Prof C Palmer, Prof A Morris, Prof B Guthrie, Dr H Parry, Dr R Tavendale, Duncan Heather, 
Lynn Rutherford, Helen Waldie, Mohanpradeep Mohan, Fatima Baig, Pippa Hopkinson, Daniel Levin FIFE 
HOSPITALS: Dr Mark Francis, Valerie Bryson, ABERDEEN ROYAL INFIRMARY: Dr Dana Dawson, Professor 
Michael Frenneaux; EDINBURGH ROYAL INFIRMARY: Dr Martin Denvir, Laura Flint, Shirley Robertson; 
GLASGOW GOLDEN JUBILEE HOSPITAL: Dr Roy Gardner, Marion McAdam, Kirsty McGovern; GLASGOW 
WESTERN INFIRMARY: Prof J McMurray, Dr Ross Campbell, Dr Jane Cannon 
 
 
17 
 
Table 1. Baseline characteristics of the Index and validation cohort of BIOSTAT-CHF 
Variable Index cohort Validation cohort 
N = 2516 1738 
Demographics   
Sex (% Male(n)) 73.4 (1846) 65.9 (1145) 
Age (years) 68.9±12         73.7±10.7 
Race (% Caucasian(n)) 98.9 (2489) 99.3 (1725) 
BMI (kg/m2) 27.9±5.5       28.1±6.4  
Weight (kg) 81.8±18.5          82.2±20.1 
Height (cm) 170.9±9.2 168±10.4 
NYHA class (%(n))   
I 2.2 (56) 1.0 (17) 
II 34.5 (868) 41.0 (712) 
III 48.8 (1228) 44.4 (772) 
IV 11.7 (294) 13.6 (236) 
LVEF (%) 31±10.6 16% Good, 79% 
Poor/Reduced 5% N/A 
Clinical Profile   
Edema (%(n)) 29.7 (624) 54.9 (955) 
Orthopnea (%(n)) 35 (879) 4.1 (71) 
Rales > 1/3 up lung fiels (%(n)) 19.2 (248) 2.9 (50) 
Jugular venous pressure (%(n)) 33.5 (554) 25.9 (450) 
Hepatomegaly (%(n)) 14.3 (358) 3.5 (60) 
Systolic Blood Pressure (mmHg) 124.7±21.9 125.9±22.6 
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Diastolic Blood Pressure (mmHg) 74.9±13.4 69.2±13.2 
Heart Rate (beats/min) 80±19.5 74.2±16.6 
Hospitalization   
Type of visit (%(n))   
Scheduled outpatient clinic 27.2 (685) 46.3 (804) 
Unscheduled outpatient clinic 5.4 (137) 0 (0) 
Inpatient hospitalization 67.3 (1694) 53.7 (934) 
Reason for visit (%(n))   
Worsening heart failure 54.5 (1372) 76.9 (1323) 
New onset heart failure 27.9 (702) 23.9 (415) 
Other 17.6 (442) 0 (0) 
Heart Failure History   
Years since first diagnosis 2.8 [0.1-9.4] 1.4 (0.1-4.7) 
Ischemic heart disease (%(n)) 60.5 (1358) 64.9 (1128) 
Previous HF hospitalization (%(n)) 31.6 (794) 26.5 (460) 
Medical History   
Hypertension (%(n)) 62.4 (1569) 57.9 (1007) 
Atrial fibrillation (%(n)) 45.4 (1143) 43.7 (760) 
Myocardial infarction (%(n)) 38.3 (963) 48.8 (849) 
PCI (%(n)) 21.6 (544) 18.7 (325) 
CABG (%(n)) 17.2 (433) 17.7 (308) 
Pacemaker (%(n)) 7.3 (183) 6.6  (115) 
ICD (%(n)) 8.1 (205) 4.0 (69) 
Biventricular pacer (CRT) (%(n)) 1.9 (49) 1.6 (27) 
19 
 
Biventricular Pacer (CRT(n)) and ICD (%(n)) 6.9 (173) 3.2 (55) 
Diabetes mellitus (%(n)) 32.6 (819) 32.3 (561) 
COPD (%(n)) 17.3 (436) 18.4 (319) 
Peripheral artery disease (%(n)) 10.9 (273) 21.5 (374) 
Stroke (%(n)) 9.3 (233) 18.1 (315) 
Medication   
ACE-inhibitors or Angiotensin receptor 
blockers (%(n)) 
72.3 (1820) 70.1 (1218) 
Target dose (%(n)) 13.4 (336) 15.2 (185) 
% of optimal dose 48±35 43±27 
Beta-blockers (%(n)) 83.2 (2093) 72.7 (1264) 
Target dose (%(n)) 5.5 (138) 17.8 (226) 
% of optimal dose 32±26 46±28 
Loop diuretics (%(n)) 99.5 (2504) 99.4 (1728) 
Aldosterone antagonists (%(n)) 53.2 (1339) 32.5 (564) 
Digoxine (%(n)) 19.5 (491) 17.9 (311) 
Laboratory   
Hemoglobin (g/dL) 13.3 [11.9-14.5] 13.2 (11.8-14.5) 
Creatinine (umol/L) 101.0 [82.6-128.2] 97.0 (79.8-125.0) 
Urea (mmol/L) 11.1 [7.4-17.7] 8.6 (6.5-11.9) 
GFR MDRD formula (ml/min/1.73m2) 67.1 [50.4-86.1] 63.3 (46.9-80.4) 
Sodium (mmol/L) 140.0 [137.0-142.0] 139.0 (137.0-141.0) 
Potassium (mmol/L) 4.2 [3.9-4.6] 4.3 (4.0-4.6) 
BNP (pg/mL) 667.8 [362-1266.5]  
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NT pro-BNP (ng/L) 4275 [2360-8485.5]  
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Table 2. Overview of biomarkers and associated pathophysiological domains 
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Albumin X         X  X 
Aldosterone            X 
ALT            X 
Alkaline phosphatase            X 
ANP    X         
AST            X 
Angiogenin       X      
BUN        X  X   
(NT-pro) BNP    X         
Calcium         X   X 
Creatinine        X     
CRP X     X       
Cystatin C X       X     
D-Dimer X           X 
Endothlin-1     X        
ESAM X     X X      
Erythrocytes           X  
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Ferritin X          X  
FGF-23            X 
Galectin-3 X X      X     
Gamma GT            X 
GDF-15 X X X   X       
Glucose          X   
HDL          X   
Hemoglobin           X  
Hematocrit           X  
Hepcidin           X  
Interleukin-6 X            
Iron           X  
LDL      X    X   
Leucocytes X          X  
LTβR X     X       
Mesothelin            X 
MR-proADM     X        
Myeloperoxidase X  X          
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Neuropilin     X  X     X 
NGAL X       X     
NT-proCNP     X        
Osteopontin X X    X X      
Procalcitonin X            
Pentraxin-3 X            
Periostin  X          X 
Phosphate         X   X 
PIGR X            
Platelets           X X 
Potassium        X X    
Pro-enkephalin            X 
PSAP-B   X         X 
RAGE X     X       
Renin            X 
sST-2 X X X X   X      
Sodium        X X    
Soluble transferrin 
receptor 
          X  
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Syndecan-1 X X           
TNFR-1 X            
Total bilirubin           X  
Total cholesterol      X    X   
Transferrin           X  
Triglycerides      X    X   
Troponin    X         
Troy X X           
VEGFR-1       X      
WAP-4C X           X 
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Figure 1. Schematic overview of the BIOSTAT-CHF project. WP= Work Package.  
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Figure 2. Example of a genetic profile, proteins and phenotypes related to the activity of the renin-
angiotensin aldosterone system that might influence the response to blockers of the renin-angiotensin 
aldosterone system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Figure 3. Rationale and design of BIOSTAT-CHF: to use a system biology approach integrating genetic, 
protein, and clinical information in order to define a responder profile to current recommended therapy 
for patients with heart failure. ACEi=angiotensin converting enzyme-inhibitor; ARB = angiotensin receptor 
blocker; BB = beta blocker; GWAS + genome wide association study; MRA = mineralocorticoid receptor antagonist; 
WHF = worsening heart failure 
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